Logo

AstraZeneca to Acquire Caelum for ~500M

Share this

M&A

AstraZeneca to Acquire Caelum for ~500M

Shots:

  • Alexion has exercised its option to acquire all remaining equity in Caelum for CAEL-101 which is currently being evaluated in P-III CARES clinical program that consists of 2 P-III trials in combination with SoC therapy for AL amyloidosis
  • Caelum to receive ~$150M as an option exercise fee in addition to ~$350M upon the achievement of regulatory & commercial milestones. The transaction is expected to close on Oct 5- 2021
  • CAEL-101 is a mAb- targeted for reducing and eliminating amyloid accumulation in patients with AL. The therapy has received ODD from the both US FDA & EC for the same indication & also received FDA’s FTD while two P-III trials in patients with Mayo stage IIIa & IIIb are ongoing

  | Ref: AstraZeneca | Image: Businesswire

Click here to­ read the full press release 

Tags

M&A

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions